---
title: "AZN.US (AZN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AZN.US/news.md"
symbol: "AZN.US"
name: "AZN.US"
parent: "https://longbridge.com/en/quote/AZN.US.md"
datetime: "2026-05-20T01:33:24.212Z"
locales:
  - [en](https://longbridge.com/en/quote/AZN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AZN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AZN.US/news.md)
---

# AZN.US (AZN.US) — Related News

### [AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension](https://longbridge.com/en/news/286904730.md)
*2026-05-19T11:34:58.000Z*
> AstraZeneca has received US approval for Baxfendy, a first-in-class aldosterone synthase inhibitor for adults with uncon

### [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
*2026-05-18T18:01:20.000Z*
> The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant mileston

### [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)
*2026-05-18T16:59:00.000Z*
> AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast ca

### [<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>](https://longbridge.com/en/news/286792193.md)
*2026-05-18T14:59:15.000Z*
> The FDA has approved Baxfendy (baxdrostat) for adults with hypertension inadequately controlled on other medications, ma

### [FDA approves Enhertu for two HER2-positive early breast cancer indications](https://longbridge.com/en/news/286740066.md)
*2026-05-18T07:49:17.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case](https://longbridge.com/en/news/286788482.md)
*2026-05-18T14:13:00.000Z*
> The US Supreme Court denied petitions from six major pharmaceutical companies, including AstraZeneca and Johnson & Johns

### [Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare](https://longbridge.com/en/news/286790537.md)
*2026-05-18T13:59:12.000Z*
> The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiation

### [<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>](https://longbridge.com/en/news/286780814.md)
*2026-05-18T13:11:58.000Z*
> The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, appro